Flu Vaccines for 2026: A Comprehensive Overview
The 2026 flu season is fast approaching, and healthcare professionals are being urged to emphasize the importance of annual influenza vaccination. Australia's Chief Medical Officer, Professor Michael Kidd, has written to medical practitioners, highlighting the critical role they play in encouraging vaccination uptake among their patients.
Professor Kidd emphasizes that a recommendation from a trusted health professional significantly influences a patient's decision to get vaccinated. Recent data reveals a concerning trend in vaccination rates, underscoring the need for proactive measures.
This year, flu vaccines have been updated with two new A strains, and the National Immunisation Program (NIP) vaccines will be available for order from April 2026. CSL Seqirus, a leading flu vaccine manufacturer, has released its vaccines, which are now accessible to clinics and pharmacies through the TGA.
Dr. Jules Bayliss, ANZ Vaccines Medical Director at CSL Seqirus, emphasizes the manufacturer's commitment to reliable vaccine supply. They will provide doctors and pharmacists with early vaccine stock, ensuring a successful vaccination campaign.
The company's cell-based and adjuvanted vaccines are available for the private market and as part of the NIP, ensuring all Australians can access tailored influenza vaccines. This comprehensive approach aims to protect individuals, families, and communities from the devastating effects of influenza.
In the European Union, the European Medicines Agency's drug advisory panel has recommended marketing authorization for Moderna's mCOMBRIAX, a groundbreaking combination flu and COVID mRNA vaccine. This development marks a significant milestone in respiratory virus vaccination and for Moderna.
Moderna's CEO, Stephane Bancel, expressed enthusiasm, stating that the recommendation signifies an important step forward for respiratory virus vaccination and Moderna. If approved, mCOMBRIAX would become Moderna's fourth marketed product in Europe, showcasing the potential of combination vaccines to simplify vaccination processes and enhance health outcomes.
For further insights, readers can explore the full Pharmacy Daily newsletter from March 2, 2026, by clicking the provided link or downloading the embedded issue.
